Ionis starts Phase 1-2 trial of ION337 for Dravet syndrome

July 13, 2026 7:01 AM

Ionis Pharmaceuticals (Nasdaq: IONS) has dosed the first participant in the Phase 1-2 ASCEND study of ION337, an investigational RNA-targeted ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found